Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 7659684, 8 pages
http://dx.doi.org/10.1155/2016/7659684
Research Article

Chitosan and Sodium Alginate Combinations Are Alternative, Efficient, and Safe Natural Adjuvant Systems for Hepatitis B Vaccine in Mouse Model

1Viral Control Unit, National Organisation for Research and Control of Biologicals (NORCB), Cairo 12654, Egypt
2Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
3National Organization for Drug Control and Research (NODCAR), Cairo 11562, Egypt

Received 1 April 2016; Accepted 9 June 2016

Academic Editor: Mario Giorgi

Copyright © 2016 Nourhan H. AbdelAllah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, Hepatitis B. Fact Sheet No. 204, 2000, World Health Organization, Geneva, Switzerland, 2007.
  2. J. F. Perz, G. L. Armstrong, L. A. Farrington, Y. J. F. Hutin, and B. P. Bell, “The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide,” Journal of Hepatology, vol. 45, no. 4, pp. 529–538, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. B. N. Fields, D. M. Knipe, P. M. Howley, and D. E. Griffin, Fields Virology, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2001.
  4. D. Lavanchy, “Hepatitis B virus epidemiology, disease burden, treatment, arid current and emerging prevention and control measures,” Journal of Viral Hepatitis, vol. 11, no. 2, pp. 97–107, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Shlomai and Y. Shaul, “Inhibition of hepatitis B virus expression and replication by RNA interference,” Hepatology, vol. 37, no. 4, pp. 764–770, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. Centers for Disease Control and Prevention (CDC), Epidemiology and Prevention of Vaccine-Preventable Diseases, Public Health Foundation, Washington, DC, USA, 2011.
  7. R. Clemens, R. Sänger, J. Kruppenbacher et al., “Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule—results of a post-marketing surveillance,” Vaccine, vol. 15, no. 4, pp. 349–352, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Cardell, B. Åkerlind, M. Sällberg, and A. Frydén, “Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine,” Journal of Infectious Diseases, vol. 198, no. 3, pp. 299–304, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. E. Itodo, J. U. Umoh, J. O. Adekeye, M. O. Odugbo, G. Haruna, and M. Y. Sugun, “Field trial of sodium alginate-adsorbed Clostridium perfringens types C and D toxoid against clostridial enterotoxemia in sheep,” Israel Journal of Veterinary Medicine, vol. 64, no. 1, pp. 2–5, 2009. View at Google Scholar · View at Scopus
  10. Y. Kato, H. Onishi, and Y. Machida, “Application of chitin and chitosan derivatives in the pharmaceutical field,” Current Pharmaceutical Biotechnology, vol. 4, no. 5, pp. 303–309, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. M. J. Heffernan, D. A. Zaharoff, J. K. Fallon, J. Schlom, and J. W. Greiner, “In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines,” Biomaterials, vol. 32, no. 3, pp. 926–932, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. M. Vasiliev, “Chitosan-based vaccine adjuvants: incomplete characterization complicates preclinical and clinical evaluation,” Expert Review of Vaccines, vol. 14, no. 1, pp. 37–53, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Leary, W. Underwood, R. Anthony et al., AVMA Guidelines for the Euthanasia of Animals, 2013.
  14. R. Scherließ, S. Buske, K. Young, B. Weber, T. Rades, and S. Hook, “In vivo evaluation of chitosan as an adjuvant in subcutaneous vaccine formulations,” Vaccine, vol. 31, no. 42, pp. 4812–4819, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Dobakhti, T. Naghibi, M. Taghikhani et al., “Adjuvanticity effect of sodium alginate on subcutaneously injected BCG in BALB/c mice,” Microbes and Infection, vol. 11, no. 2, pp. 296–301, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. L. C. Chosewood and D. E. Wilson, Biosafety in Microbiological and Biomedical Laboratories, Diane Publishing, 2007.
  17. O. Borges, M. Silva, A. de Sousa, G. Borchard, H. E. Junginger, and A. Cordeiro-da-Silva, “Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen,” International Immunopharmacology, vol. 8, no. 13-14, pp. 1773–1780, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Y. Li, X. Y. Kong, S. Shi et al., “Preparation of alginate coated chitosan microparticles for vaccine delivery,” BMC Biotechnology, vol. 8, article 89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. T. L. Stevens, A. Bossie, V. M. Sanders et al., “Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells,” Nature, vol. 334, no. 6179, pp. 255–258, 1988. View at Publisher · View at Google Scholar · View at Scopus
  20. Z.-S. Wen, Y.-L. Xu, X.-T. Zou, and Z.-R. Xu, “Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice,” Marine Drugs, vol. 9, no. 6, pp. 1038–1055, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Xie, N.-J. Zhou, Y.-F. Gong et al., “Th immune response induced by H pylori vaccine with chitosan as adjuvant and its relation to immune protection,” World Journal of Gastroenterology, vol. 13, no. 10, pp. 1547–1553, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. A. C. Boesteanu, N. S. Babu, M. Wheatley, E. S. Papazoglou, and P. D. Katsikis, “Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus,” Vaccine, vol. 29, no. 2, pp. 314–322, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. R. K. Gherardi, M. Coquet, P. Cherin et al., “Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle,” Brain, vol. 124, no. 9, pp. 1821–1831, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. E. B. Lindblad, “Aluminium compounds for use in vaccines,” Immunology and Cell Biology, vol. 82, no. 5, pp. 497–505, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Arai, T. Kinumaki, and T. Fujita, “Toxicity of chitosan,” Bulletin of Tokai Regional Fisheries Research Laboratory, no. 56, pp. 89–94, 1968. View at Google Scholar
  26. T. Kean and M. Thanou, “Biodegradation, biodistribution and toxicity of chitosan,” Advanced Drug Delivery Reviews, vol. 62, no. 1, pp. 3–11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. W. Wang and M. Singh, “Selection of adjuvants for enhanced vaccine potency,” World Journal of Vaccines, vol. 1, no. 2, pp. 33–78, 2011. View at Publisher · View at Google Scholar
  28. S. Romagnani, “T-cell subsets (Th1 versus Th2),” Annals of Allergy, Asthma & Immunology, vol. 85, no. 1, pp. 9–21, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. J. A. Gracie and J. A. Bradley, “Interleukin-12 induces interferon-γ-dependent switching of IgG alloantibody subclass,” European Journal of Immunology, vol. 26, no. 6, pp. 1217–1221, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Levast, S. Awate, L. Babiuk et al., “Vaccine potentiation by combination adjuvants,” Vaccines, vol. 2, no. 2, pp. 297–322, 2014. View at Publisher · View at Google Scholar
  31. Y. Perrie, A. R. Mohammed, D. J. Kirby, S. E. McNeil, and V. W. Bramwell, “Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens,” International Journal of Pharmaceutics, vol. 364, no. 2, pp. 272–280, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. M. E. Pichichero, “Improving vaccine delivery using novel adjuvant systems,” Human Vaccines, vol. 4, no. 4, pp. 262–270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Clapp, P. Siebert, D. Chen, and L. Jones Braun, “Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability,” Journal of Pharmaceutical Sciences, vol. 100, no. 2, pp. 388–401, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Hansen, A. Sokolovska, H. HogenEsch, and S. L. Hem, “Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response,” Vaccine, vol. 25, no. 36, pp. 6618–6624, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Weeratna, L. Comanita, and H. L. Davis, “CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice,” Immunology and Cell Biology, vol. 81, no. 1, pp. 59–62, 2003. View at Publisher · View at Google Scholar · View at Scopus